Innovent Biologics Joins HSI and Two Other Key Indices
Innovent Biologics Joins Hang Seng Index: Innovent Biologics has been added to the Hang Seng Index (HSI) as part of the Q3 2025 quarterly review, marking a significant achievement for the company.
First Biotech to Achieve This Milestone: This inclusion makes Innovent the first company to transition from a biotech to a leading biopharma and be recognized in the HSI, highlighting its growth and success in the industry.
Additional Index Admissions: Alongside its HSI inclusion, Innovent has also been admitted to the Hang Seng China Enterprises Index (HSCEI) and the Hang Seng ESG Enhanced Index, further solidifying its market presence.
Significance for Hong Kong's Core Assets: The addition of Innovent to these indices underscores its role as a representative of Hong Kong's core assets and the growing importance of biopharma in the region.
About the author









